Rumalon injection solution ampoules 1ml N10
Condition: New product
972 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Glycosaminoglycan-peptide complex
Release form
Solution
Composition
Active ingredient: glycosaminoglycan-peptide complex of cartilage and bone marrow of young calves up to 6 months. Concentration of active ingredient (%): 100%
Pharmacological effect
Pharmacological action - stimulating the regeneration of cartilage tissue. Enhances the biosynthesis of sulfated mucopolysaccharides and stimulates regeneration in the cartilage hyaline tissue, inhibits catabolic processes in cartilage.
Pharmacokinetics
Studies have not been conducted.
Indications
Osteoarthritis, spondyloarthrosis (spinal disease), meniscopathy (cartilage disease of the knee joint, accompanied by pain and disruption of its function), patellar hondromallation (necrosis of the articular cartilage of the patella).
Contraindications
Hypersensitivity to the drug.
Use during pregnancy and lactation
The use of the drug during pregnancy and during breastfeeding is contraindicated (due to the lack of information about the use of the drug in these groups of patients).
Dosage and administration
It is used only for intramuscular injections. After determining the tolerability of the drug (introduction of 0.25 ml, and then, with an interval of 2 days, the introduction of 0.5 ml), it is administered in the amount of 1 or 2 ml 2-3 times a week. The course includes 25 injections of 1 ml or 15 injections of 2 ml. The courses of injections are repeated 2 times a year (in severe cases, 3-4 times a year) for many years.
Side effects
Allergic reactions (rare).
Overdose
So far, cases of overdose are not registered.
Interaction with other drugs
The drug Rumalon can be used simultaneously with NSAIDs and GCS. When used simultaneously with indirect anticoagulants, antiplatelet agents and fibrinolytics, it is possible to enhance their action.
special instructions
With simultaneous use with indirect anticoagulants, antiplatelet agents and fibrinolytics, frequent monitoring of blood coagulation indices is necessary. Effect on ability to drive vehicles and mechanismsThe use of the drug does not affect the ability to perform potentially hazardous activities that require increased concentration of attention and quickness of psychomotor reactions (control vehicles, work with moving mechanisms, the work of the dispatcher and the operator).